Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy - Luxembourg, B; Schneider, K; Sittinger, K (Thromb Haemost, 2011)
et al.